Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

101. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. Full Text available with Trip Pro

Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. To investigate whether placebo effects can experimentally be separated into the response to three components-assessment and observation, a therapeutic ritual (placebo treatment), and a supportive patient-practitioner relationship-and then progressively combined to produce incremental clinical improvement in patients with irritable bowel syndrome. To assess the relative magnitude

2008 BMJ Controlled trial quality: predicted high

102. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized controlled trials

Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

103. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

104. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials

Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

105. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

16 years or over, with irritable bowel syndrome (IBS) not related to organic disease and diagnosed according to specific criteria (i.e. Manning, Kruis score, Rome I, II or III), were eligible for inclusion. Eligible studies were required to include treatment duration of at least one week and at least one week follow-up. Studies were also required to report a global assessment of cure or improvement of symptoms, or cure or improvement of abdominal pain, as reported by the patient or health (...) Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis Ford A C, Talley N J, Spiegel B M, Foxx-Orenstein A E, Schiller L, Quigley E M, Moayyedi P CRD

2008 DARE.

106. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Full Text available with Trip Pro

that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA 2008; 300(15): 1793-1805 PubMedID DOI Other publications of related interest Bursey F. Review: combinations of clinical findings had moderate sensitivity and specificity for diagnosing the irritable bowel syndrome. APC Journal Club 2009;150:13 Indexing Status Subject indexing assigned by NLM MeSH Abdominal Pain /etiology; Diagnosis, Differential; Diarrhea /etiology; Humans; Irritable Bowel Syndrome /diagnosis (...) Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Ford A C, Talley N J, Velhuyzen van Zenten

2008 DARE.

107. Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials

that there was no statistically significant evidence that selective serotonin reuptake inhibitors (SSRIs) improved abdominal pain, bloating or irritable bowel syndrome (IBS) symptoms, although there was a trend for improvement in abdominal pain. In view of methodological limitations in the review, in particular the failure to adequately address heterogeneity, the conclusions may not be reliable. Authors' objectives To determine the efficacy of selective serotonin reuptake inhibitors (SSRIs) for irritable bowel syndrome (IBS (...) Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials Rahimi R, Nikfar S, Abdollahi M CRD summary The authors stated

2008 DARE.

108. The relationship between somatisation and outcome in patients with severe irritable bowel syndrome

The relationship between somatisation and outcome in patients with severe irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

109. Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome

Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

110. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting (Abstract)

to placebo. Renzapride was well tolerated at all doses.This study confirms the gastrointestinal prokinetic effects of renzparide. The data also suggested a potentially beneficial effect on abdominal pain/discomfort in women with constipation-predominant irritable bowel syndrome. (...) Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting Relatively few pharmacological treatment options are available for treating patients with irritable bowel syndrome. New and effective medicines are urgently required.To identify an appropriate dosage of renzapride (a 5-HT(4) receptor full agonist/5-HT(3) receptor antagonist) to treat abdominal pain/discomfort

2008 EvidenceUpdates Controlled trial quality: predicted high

111. Hypnotherapy for Children With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Controlled Trial. (Abstract)

Hypnotherapy for Children With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Controlled Trial. BACKGROUND & AIMS: Functional abdominal pain (FAP) and irritable bowel syndrome (IBS) are highly prevalent in childhood. A substantial proportion of patients continues to experience long-lasting symptoms. Gut-directed hypnotherapy (HT) has been shown to be highly effective in the treatment of adult IBS patients. We undertook a randomized controlled trial and compared clinical (...) effectiveness of HT with standard medical therapy (SMT) in children with FAP or IBS. METHODS: Fifty-three pediatric patients, age 8-18 years, with FAP (n = 31) or IBS (n = 22), were randomized to either HT or SMT. Hypnotherapy consisted of 6 sessions over a 3-month period. Patients in the SMT group received standard medical care and 6 sessions of supportive therapy. Pain intensity, pain frequency, and associated symptoms were scored in weekly standardized abdominal pain diaries at baseline, during therapy

2007 EvidenceUpdates Controlled trial quality: uncertain

112. Hypnotherapy for treatment of irritable bowel syndrome. Full Text available with Trip Pro

Hypnotherapy for treatment of irritable bowel syndrome. Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder of unknown aetiology. Current pharmacological treatments have limited value. Hypnotherapy has been reported to have beneficial effects for IBS symptoms.To evaluate the efficacy of hypnotherapy for the treatment of irritable bowel syndrome.Published and unpublished randomised clinical trials and quasi-randomised clinical trials were identified through structured (...) for the treatment of irritable bowel syndrome with no treatment or another therapeutic intervention.All studies were evaluated for eligibility for inclusion. Included studies were assessed for quality and data were extracted independently by four authors. The primary outcome measure of interest was the overall bowel symptom severity score which combines abdominal pain, diarrhoea or constipation and bloating. Secondary outcomes included abdominal pain, diarrhoea, constipation, bloating, quality of life

2007 Cochrane

113. Economic evaluation of tegaserod vs placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study

Economic evaluation of tegaserod vs placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

114. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: a randomised controlled trial Full Text available with Trip Pro

Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: a randomised controlled trial Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: a randomised controlled trial Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested (...) could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} The trial found that specially trained practice nurses can provide effective cognitive behavioural therapy (CBT) to primary care patients with a clinical diagnosis of irritable bowel syndrome, however CBT does not reduce service or social costs. It was also found

2006 NIHR HTA programme

115. The efficacy of antidepressants and various psychotherapies as adjunctive treatments for irritable bowel syndrome (IBS).

The efficacy of antidepressants and various psychotherapies as adjunctive treatments for irritable bowel syndrome (IBS). Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here

2006 University of Texas at Austin School of Nursing, Family Nurse Practitioner Program

116. Herbal medicines for treatment of irritable bowel syndrome. Full Text available with Trip Pro

Herbal medicines for treatment of irritable bowel syndrome. Traditional herbal therapies have been used for a long time to treat gastrointestinal disorders including irritable bowel syndrome, and their effectiveness from clinical research evidence needs to be systematically reviewed.To assess the effectiveness and safety of herbal medicines in patients with irritable bowel syndrome.We searched the following electronic databases till July 2004: The Cochrane Library (CENTRAL), MEDLINE, EMBASE (...) of randomised participants.Seventy-five randomised trials, involving 7957 participants with irritable bowel syndrome, met the inclusion criteria. The methodological quality of three double-blind, placebo-controlled trials was high, but the quality of remaining trials was generally low. Seventy-one different herbal medicines were tested in the included trials, in which herbal medicines were compared with placebo or conventional pharmacologic therapy. Herbal medicines were also combined with conventional

2006 Cochrane

117. Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome

Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

118. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial

Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial Kennedy T M, Chalder T, McCrone P, Darnley S, Knapp M, Jones R H, Wessely S (...) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Kennedy T M, Chalder T, McCrone P, Darnley S, Knapp M, Jones R H, Wessely S. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial. Health Technology Assessment 2006; 10(19): 1-84 Authors' objectives The aim

2006 Health Technology Assessment (HTA) Database.

119. Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review

Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review Bian Z, Wu T, Liu L, Miao J, Wong H, Song L, Sung J J CRD summary The review assessed the Chinese herbal medicine TongXieYaoFang for irritable bowel syndrome. The authors (...) concluded that TongXieYaoFang together with other Chinese medicinal herbs has the potential to improve symptoms of irritable bowel syndrome more than conventional medicines. It is highly likely that the evidence reviewed was biased towards results in favour of TongXieYaoFang. Authors' objectives To evaluate the effectiveness of TongXieYaoFang (TXYF) with or without additional Chinese herbal medicines for the management of irritable bowel syndrome (IBS). Searching MEDLINE, EMBASE, the Cochrane Controlled

2006 DARE.

120. A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome

A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.